CliffBio
biologic

Pancreaze

pancrelipase

Loss of exclusivityMarch 2026projected — 12-year biologic exclusivity estimate
CompanyVivus, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand namePancreaze
Active ingredientpancrelipase
Strength2,600USP UNITS; 8,800USP UNITS; 15,200USP UNITS
Dosage formCapsule, Delayed Release
RouteOral
ModalityBiologic
FDA approvalMarch 2014
Marketing statusRx

More from Vivus, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Pancreaze patent cliff — loss of exclusivity March 2026 | CliffBio